Published in Liver Int on November 01, 2008
Survey of adult liver transplantation techniques (SALT): an international study of current practices in deceased donor liver transplantation. HPB (Oxford) (2011) 0.81
Deciding liver transplant candidacy: tools of the trade. Liver Int (2008) 0.80
Recipient ineligibility after liver transplantation assessment: a single centre experience. Can J Surg (2013) 0.80
Liver transplantation trends in the HIV population. Dig Dis Sci (2011) 0.79
Liver transplantation for alcoholic liver disease: a devilish dilemma. Can J Gastroenterol (2013) 0.75
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 3.64
Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl (2012) 2.26
Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol (2003) 2.17
Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis (2007) 2.16
Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology (2004) 2.16
Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med (2002) 2.06
Choledochal cysts: part 1 of 3: classification and pathogenesis. Can J Surg (2009) 1.91
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl (2004) 1.80
Exploring the psychological effects of deceased organ donation on the families of the organ donors. Clin Transplant (2008) 1.75
Granulomatous hepatitis associated with etanercept therapy. J Rheumatol (2008) 1.56
Severe desflurane hepatotoxicity after colon surgery in an elderly patient. Can J Anaesth (2005) 1.55
Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl (2009) 1.55
Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial. Clin Gastroenterol Hepatol (2008) 1.50
Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology (2002) 1.50
Pregnancy and sexual function in liver transplantation. J Hepatol (2008) 1.49
Cross-sectional study of hepatitis B awareness among Chinese and Southeast Asian Canadians in the Vancouver-Richmond community. Can J Gastroenterol (2005) 1.47
Imaging appearance in acute liver failure: correlation with clinical and pathology findings. Dig Dis Sci (2014) 1.39
Spatulated end-to-end bile duct reconstruction in orthotopic liver transplantation. Clin Transplant (2007) 1.39
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology (2010) 1.38
Clozapine-induced fatal fulminant hepatic failure: a case report. Can J Gastroenterol (2009) 1.22
Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma (2005) 1.21
Choledochal cysts. Part 3 of 3: management. Can J Surg (2010) 1.21
Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British Columbia. Can J Gastroenterol Hepatol (2015) 1.19
Gastric polyps in patients with portal hypertension. Eur J Gastroenterol Hepatol (2011) 1.16
Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology (2005) 1.15
Percutaneous liver biopsy practice patterns among Canadian hepatologists. Can J Gastroenterol (2013) 1.15
Comparison of acoustic radiation force impulse imaging (ARFI) to liver biopsy histologic scores in the evaluation of chronic liver disease: A pilot study. Ann Hepatol (2010) 1.14
Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol (2012) 1.13
Pathophysiologic observations and histopathologic recognition of the portal hyperperfusion or small-for-size syndrome. Am J Surg Pathol (2006) 1.12
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation (2007) 1.11
Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol (2009) 1.10
Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: Analysis of UNOS Database. Transplantation (2006) 1.10
Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol (2013) 1.10
Does this patient with liver disease have cirrhosis? JAMA (2012) 1.09
Budd-Chiari syndrome: in evolution. Eur J Gastroenterol Hepatol (2005) 1.05
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics (2003) 1.05
A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol (2012) 1.05
Choledochal cysts: part 2 of 3: Diagnosis. Can J Surg (2009) 1.03
Acute fatty liver of pregnancy. Can J Gastroenterol (2006) 1.03
Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transpl (2002) 1.01
Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans. Hepatology (2013) 1.01
Prediction of cardiac complications after liver transplantation. Transplantation (2009) 1.00
Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol (2014) 1.00
Primary hepatic neuroendocrine tumour requiring live donor liver transplantation: case report and concise review. Ann Hepatol (2012) 0.99
The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol (2007) 0.98
Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl (2005) 0.98
The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int (2008) 0.98
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98
Polycystic liver disease: experience at a teaching hospital. Am J Gastroenterol (2005) 0.96
Prevalence of occult gastrointestinal bleeding in celiac disease. Clin Gastroenterol Hepatol (2006) 0.96
A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol (2009) 0.96
Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl (2002) 0.96
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology (2008) 0.95
Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure. Crit Care (2007) 0.95
Predictors of relapse to significant alcohol drinking after liver transplantation. Can J Gastroenterol (2010) 0.94
Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol (2008) 0.93
Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev (2011) 0.93
Parvovirus B19 in an immunocompetent adult patient with acute liver failure: an underdiagnosed cause of acute non-A-E viral hepatitis. Can J Gastroenterol (2005) 0.93
Post-liver transplant Crohn's disease: graft tolerance but not self-tolerance? Dig Dis Sci (2002) 0.93
Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C. World J Gastroenterol (2006) 0.92
Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians. Can J Gastroenterol (2008) 0.91
ABO-incompatible liver transplantation for critically ill adult patients. Transpl Int (2007) 0.91
Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol (2012) 0.91
Duplex Doppler ultrasound of the hepatic artery in patients with acute alcoholic hepatitis. J Clin Gastroenterol (2002) 0.91
Late acute celiac and hepatic artery thrombosis with portal vein thrombosis resulting in hepatic infarction 12 years post orthotopic liver transplantation. Ann Hepatol (2009) 0.91
Live donor liver transplantation without blood products: strategies developed for Jehovah's Witnesses offer broad application. Ann Surg (2004) 0.90
Hepatic dysfunction in hyperthyroidism. Gastroenterol Hepatol (N Y) (2011) 0.90
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol (2011) 0.90
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy. Pharmacotherapy (2008) 0.89
Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol (2005) 0.89
Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. Dig Dis Sci (2014) 0.88
Sphincter of Oddi dysfunction: managing the patient with chronic biliary pain. World J Gastroenterol (2006) 0.88
Parvovirus B19 induced hepatic failure in an adult requiring liver transplantation. World J Gastroenterol (2009) 0.88
Alcohol use while on the liver transplant waiting list: a single-center experience. Liver Transpl (2010) 0.88
Effects of upper extremity exercise training on peak aerobic and anaerobic fitness in patients after transplantation. Am J Cardiol (2004) 0.87
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol (2006) 0.87
Hepatology and the Canadian gastroenterologist: interest, attitudes and patterns of practice: results of a national survey from the Canadian Association of Gastroenterology. Can J Gastroenterol (2003) 0.87
Development of anti-CCP-positive rheumatoid arthritis following pegylated interferon-α2a treatment for chronic hepatitis C infection. J Rheumatol (2010) 0.87
Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community. Can J Gastroenterol (2007) 0.86
Spontaneous clearance of hepatitis C infection post-liver transplant: A rare but real phenomenon? A case report and review of the literature. Ann Hepatol (2010) 0.86
Transient elastography in Canada: Current state and future directions. Can J Gastroenterol Hepatol (2015) 0.85
Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol (2006) 0.85
Transient improvement of acquired hepatocerebral degeneration with parkinsonian symptoms after failed liver transplant: case report and literature review. Exp Clin Transplant (2011) 0.85
Does cirrhosis affect quality of life in hepatitis C virus-infected patients? Liver Int (2009) 0.84
In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can J Gastroenterol (2013) 0.83
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol (2003) 0.83
First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder. Ann Hepatol (2013) 0.83
Ethnic variation in the annual rates of adult inflammatory bowel disease in hospitalized patients in Vancouver, British Columbia. Can J Gastroenterol (2011) 0.83
Nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes. Can J Gastroenterol (2003) 0.83
Response to endoscopic therapy for biliary anastomotic strictures in deceased versus living donor liver transplantation. Hepatobiliary Pancreat Dis Int (2013) 0.83